Moderna Inc.

Rare Metabolic Disorders

Research activity includes propionic acidemia, isolated methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency, methylmalonic acidemia, phenylketonuria, and glycogen storage disease type 1a, with a focus on inherited conditions affecting metabolic function.

  • Propionic acidemia
  • Isolated methylmalonic acidemia
  • Phenylketonuria
  • Glycogen storage disease type 1a

These studies reflect interest in disorders with early onset, recurrent metabolic decompensation, and long-term disease burden.

Respiratory Viral Vaccines

The sponsor is active in influenza, respiratory syncytial virus, SARS-CoV-2 infection, and acute lower respiratory infection, supporting vaccine research across seasonal and pandemic respiratory threats.

  • Influenza
  • Respiratory syncytial virus
  • SARS-CoV-2 infection
  • Acute lower respiratory infection

Clinical interest spans adult protection, prevention of medically attended illness, and coverage across changing respiratory virus strains.

Maternal and Infant Immunization

Research also extends to pregnancy and early-life protection, with studies involving maternal vaccination and infant safety assessments for cytomegalovirus infection prevention.

  • Pregnancy
  • Infant safety
  • Cytomegalovirus infection
  • Maternal immunization

This area includes immune protection during gestation and disease prevention in newborns and young infants.

Long-term Safety and Ongoing Disease Management

Several trials focus on long-term safety, tolerability, and continued clinical follow-up in chronic diseases, including metabolic and infectious conditions.

  • Long-term safety
  • Tolerability
  • Chronic disease follow-up
  • Clinical activity

These studies cover repeat observation in participants previously enrolled in earlier research programs and sustained assessment of treatment-related outcomes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    2 1 1 1
    Germany Italy Poland Spain
  • A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

    Recruiting

    1 1 1
    France The Netherlands Spain
  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    2 1 1 1
    France Italy The Netherlands Spain
  • Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

    Recruiting

    2 1 1 1
    France The Netherlands Spain
  • A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark
  • Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Estonia Finland France Germany Italy +1